Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03938740
Recruitment Status : Completed
First Posted : May 6, 2019
Last Update Posted : April 2, 2020
Sponsor:
Information provided by (Responsible Party):
Diasome Pharmaceuticals

Brief Summary:
Multi-center, open-label, multiple dose safety, tolerability and efficacy study

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Drug: HDV-Insulin Lispro and Insulin Degludec (-40%) Drug: HDV-Insulin Lispro and Insulin Degludec (-10%) Phase 2

Detailed Description:
This is a 24-week, open-label, multiple dose safety, tolerability and efficacy study. There is a 12-week run-in phase when all subjects receive Insulin Lispro and Insulin Degludec for 12 weeks. After completing the run-in period, subjects then are randomized to a treatment group of either HDV- Insulin lispro + Insulin Degludec (Degludec dose reduced by 40%) or HDV-Insulin lispro+ Insulin Degludec (Degludec dose reduced by 10%) for 12 weeks of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Exploratory Randomized Open-Label 2-Arm Comparison of Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec to Determine Optimum Basal Insulin Dosing Regimens in Type 1 Diabetes Mellitus Subjects
Actual Study Start Date : March 18, 2019
Actual Primary Completion Date : December 6, 2019
Actual Study Completion Date : March 18, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
Drug: HDV-Insulin Lispro and Insulin Degludec (-40%)
HDV-Insulin Lispro and Insulin Degludec (-40%)

Experimental: HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
Drug: HDV-Insulin Lispro and Insulin Degludec (-10%)
HDV-Insulin Lispro and Insulin Degludec (-10%)




Primary Outcome Measures :
  1. Basal, bolus and total insulin doses (UOM=units) during the last 2 weeks of the treatment period [ Time Frame: 24 weeks ]
    Basal, bolus and total insulin doses (UOM=units) during the last 2 weeks of the treatment period

  2. Basal/bolus ratios during the last 2 weeks of the treatment period [ Time Frame: 24 weeks ]
    Basal/bolus ratios during the last 2 weeks of the treatment period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female of age 18 to 65 years, inclusive.
  2. If female of child-bearing potential, must agree for the duration of the study. to use adequate contraceptive measures, such as, intra-uterine device [IUD], oral or injectable contraceptives, or barrier method plus spermicide.
  3. Has at Screening been diagnosed as T1DM for at least 12 months.
  4. Has at Screening C-peptide ≤0.8 ng/mL (single retest allowed).
  5. Has at Screening been on treatment with rapid analog insulin for the previous six (6) months.
  6. Has at Screening willingness to use continuous glucose monitoring (CGM) technology throughout study.
  7. Is, for the duration of the study, willing to use insulin lispro as the only analog bolus insulin and insulin degludec as the only basal insulin.
  8. Has at Screening a BMI ≥18.0 kg/m2 and ≤33.0 kg/m2.
  9. Has at Screening HbA1c ≥6.5% and ≤8.5%.

Exclusion Criteria:

  1. Has known or suspected allergy to any component of any of the study drugs in this trial.
  2. Is, at Screening, pregnant or breast-feeding, or intends to become pregnant at any time during the duration of the study.
  3. Has, at Screening, as judged by the Site Investigator, a history or current evidence of any of the following complications of diabetes: proliferative retinopathy or maculopathy, severe neuropathy (in particular, autonomic neuropathy), symptomatic gastroparesis.
  4. Is, at Screening, judged by the Site Investigator to have a current addiction to alcohol or substances of abuse.
  5. Is, at Screening, using one or more drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia (e.g., beta blockers, systemic corticosteroids at pharmacologic doses, cancer chemotherapies.).
  6. Has at Screening any of the following findings, unless approved by both the Site Investigator and the Medical Monitor:

    • Uncontrolled hypertension, defined as diastolic blood pressure ≥ 100 mmHg and/or systolic blood pressure ≥ 160 mmHg after 5 minutes in the sitting position;
    • History of or findings on EKG of cardiac arrhythmia or conduction defect;
    • Clinically significant abnormalities on Screening laboratory studies
  7. Has, within one (1) month prior to Screening, used either oral anti-diabetic medication or non-insulin anti-diabetic injection therapies (e.g. SGLT-2 inhibitors, pramlintide, GLP-1 agonists, etc.).
  8. Has, within one (1) month prior to Screening, received any investigational drug.
  9. Has, within two (2) months prior to Screening, used an insulin pump delivery system.
  10. Has, within three (3) months prior to Screening, smoked tobacco or used any smokeless tobacco or nicotine delivery system (inhaled, oral or buccal).
  11. Has at Screening, as judged by the Site Investigator, any condition (intrinsic or extrinsic) that could reasonably be expected to interfere with trial participation, confound evaluation of the data, or pose additional risk to adhering to the study protocol. Examples of such conditions include but are not limited to:

    • Clinically significant active disease of the gastrointestinal, cardiovascular, hepatic, neurological, renal, genitourinary, or hematological systems;
    • History of such an illness or disease
    • Diminished mental capacity, psychological or behavioral dysfunction, unwilling or resistant to protocol requirements, language barriers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03938740


Locations
Layout table for location information
United States, California
Mills-Peninsula Medical Center, Diabetes Research Institute
San Mateo, California, United States, 94401
United States, Colorado
Barbara Davis Center for Diabetes
Aurora, Colorado, United States, 80045
United States, Georgia
Atlanta Diabetes Associates
Atlanta, Georgia, United States, 30318
Endocrine Research Solutions, Inc.
Roswell, Georgia, United States, 30076
United States, North Carolina
Diabetes & Endocrinology Consultants, PC
Morehead City, North Carolina, United States, 28557
United States, Texas
Texas Diabetes & Endocrinology, PA
Austin, Texas, United States, 78749
Texas Diabetes & Endocrinology, PA
Round Rock, Texas, United States, 78681
Sponsors and Collaborators
Diasome Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Marc Penn, MD, PhD Diasome Pharmaceuticals
Layout table for additonal information
Responsible Party: Diasome Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03938740    
Other Study ID Numbers: DP 01-2019-01
First Posted: May 6, 2019    Key Record Dates
Last Update Posted: April 2, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Insulin, Globin Zinc
Insulin Lispro
Insulin, Long-Acting
Hypoglycemic Agents
Physiological Effects of Drugs